Loading clinical trials...

COMPLETEDPhase 2/3NCT01265667

Trial of CF101 to Treat Patients With Psoriasis

Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.

Lead sponsor: Can-Fite BioPharma•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792 · Plaque Psoriasis

RECRUITINGPhase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453 · Plaque Psoriasis

RECRUITINGPhase 3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967 · Plaque Psoriasis

RECRUITINGPhase 3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802 · Plaque Psoriasis

RECRUITINGPhase 2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702 · Plaque Psoriasis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 18, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2/PHASE3

Enrollment293

Start dateJul 2011

Last updatedNov 18, 2020

Condition

Plaque Psoriasis

Locations shown

Mount Sinai School of Medicine

New York, New York

UMHAT "G.stranski"

Pleven

MHAT "Tokuda hospital Sofia"

Sofia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2020Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial of CF101 to Treat Patients With Psoriasis

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Trial snapshot

Condition

Locations shown

For caregivers